NexImmune (NEXI): Volume dodolan mangsa ngarep perusahaan

Logo grafis NexImmune (NEXI)

NexImmune, Inc. (NEXI) is liquidating its laboratories and returning capital to shareholders following the failure of clinical trials. Planned divestment volumes confirm this downturn, where the 0.00 mark serves as the current indicator. Previously, the business relied on robotic bioreactor control for drug scaling, while its monetization potential was based on developing immunotherapeutic cell activation methods for collaboration with pharma behemoths.

Prakiraan pendapatan perusahaan: NexImmune, Inc. (NEXI) kanggo 04.07.2022 - 04.08.2024

NEXI (NexImmune, Inc.): rincian analitis lan laporan miturut indikator

- nilai saham lan prakiraan konsensus rega:
Ringkesan analisis perusahaan:NexImmune
Sampel barang NexImmune Corporation

NexImmune, Inc. (NEXI) is scaling its AIM nanotechnology platform to expand within the tumor immunotherapy sector. An analysis of the firm's sales volume expectations allows for an assessment of the resilience of future cash flows to market shocks. This metric aggregates the value of confirmed contracts and current shipments, measuring the speed of the business's adaptation to logistical disruptions. Rising values confirm a margin of safety, while a decline signals risks of profit shortfalls. The asset is classified as a high-risk speculative security.

Pesaing langsung

Prakiraan pendapatan perusahaan ImmunityBio Inc (IBRX)|Volume dodolan mangsa ngarep perusahaan Immunocore PLC IMCR|Janux Therapeutics Inc - Volume dodolan mangsa ngarep perusahaan|Prakiraan volume dodolan Arcus Corp RCUS|ZYME - Prakiraan pendapatan perusahaan|TNGX (tangotx.com) - Prakiraan pendapatan perusahaan|Iovance Corp (IOVA) - Prakiraan pendapatan perusahaan|Volume dodolan sing dikarepake perusahaan Immatics Corp (IMTX)|Volume dodolan mangsa ngarep perusahaan XNCR|CMPX - Prakiraan dodolan perusahaan|Volume dodolan mangsa ngarep perusahaan REPL (Replimune Corp)|Prakiraan volume pendapatan perusahaan LYEL|Prakiraan volume dodolan IPHA (Innate Pharma)|Pendapatan mangsa ngarep perusahaan PYXS|Compugen Limited - Prakiraan volume dodolan|Volume dodolan sing dikarepake perusahaan IO Biotech Inc.|Sutro Biopharma, Inc. (STRO) - Prakiraan pendapatan perusahaan|MiNK Therapeutics, Inc. - Pendapatan mangsa ngarep perusahaan|HOWL (Werewolf) - Prakiraan volume dodolan|Prakiraan volume dodolan immixbio.com|Prakiraan pendapatan perusahaan ALX Oncology Holdings (ALXO)|CUE - Volume dodolan sing dikarepake perusahaan|PDS Biotechnology Corporation - Volume dodolan mangsa ngarep perusahaan|Sonnet BioTherapeutics (SONN) - Volume dodolan sing dikarepake perusahaan|MAIA - Prakiraan pendapatan perusahaan|LIMN: Prakiraan pendapatan perusahaan|LVTX: Prakiraan volume dodolan|Volume dodolan sing dikarepake perusahaan NextCure, Inc. (NXTC)|LPTX (Leap Tx) - Prakiraan volume dodolan|INTS (Intensity Therapeutics) - Prakiraan volume pendapatan perusahaan|Prakiraan pendapatan perusahaan Sensei Bio (SNSE)|TOVX (Theriva Biologics) - Pendapatan mangsa ngarep perusahaan|Prakiraan pendapatan perusahaan gritstonebio.com GRTS|Pendapatan mangsa ngarep perusahaan KA|TSBX: Volume dodolan mangsa ngarep perusahaan|VCNX (Vaccinex, Inc.) - Prakiraan pendapatan perusahaan|Harpoon Tx (HARP) - Prakiraan pendapatan perusahaan